Nab-Paclitaxel (paclitaxel protein-bound particles for injectable suspension)
Abraxis BioScience / Celgene (brand: Abraxane); generics available including Ciplo formulation · Taxane / Microtubule Stabilizer (Albumin-Bound Formulation)
What is Nab-Paclitaxel? Nab-paclitaxel (paclitaxel protein-bound) is an albumin-bound formulation of paclitaxel that does not require Cremophor EL as a solvent, avoiding many of the hypersensitivity reactions and premedication requirements associated with conventional paclitaxel. The brand Abraxane is FDA-approved for breast cancer, NSCLC, and pancreatic cancer.
About Nab-Paclitaxel
| Brand Name | Nab-Paclitaxel |
| Generic / INN | paclitaxel protein-bound particles for injectable suspension |
| Drug Class | Taxane / Microtubule Stabilizer (Albumin-Bound Formulation) |
| Manufacturer | Abraxis BioScience / Celgene (brand: Abraxane); generics available including Ciplo formulation |
| Administration | Intravenous (IV) infusion |
| FDA Approval | 2005 |
FDA-Approved Uses for Nab-Paclitaxel
Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.
- Metastatic breast cancer — after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy
- Non-small cell lung cancer (NSCLC) — first-line with carboplatin
- Metastatic adenocarcinoma of the pancreas — first-line with gemcitabine
How Does Nab-Paclitaxel Work?
Nab-paclitaxel consists of paclitaxel bound to albumin nanoparticles (~130 nm). Albumin-bound paclitaxel leverages albumin transport pathways (including SPARC-mediated and gp60-mediated transcytosis) to deliver paclitaxel to tumor tissue. Once in the tumor microenvironment, paclitaxel binds beta-tubulin, stabilizing microtubules and blocking mitosis.
Dosage & Administration
Dosing depends on indication and combination regimen, determined by the oncologist based on BSA. Nab-paclitaxel does NOT require premedication for hypersensitivity prophylaxis that conventional Cremophor-based paclitaxel requires, though institutional protocols vary.
Warnings, Precautions & Side Effects
General Warning
Myelosuppression (neutropenia is dose-limiting). Sensory neuropathy — can be severe and cumulative. Do NOT substitute nab-paclitaxel for other paclitaxel formulations on a mg-per-mg basis — they are NOT interchangeable. Hepatic impairment requires dose adjustment. Embryo-fetal toxicity.
Common Side Effects
- Peripheral neuropathy
- Neutropenia
- Alopecia
- Fatigue
- Nausea
- Diarrhea
- Myalgia/arthralgia
This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.
Storage & Handling
Intact vials: store at room temperature 20°C to 25°C (68°F to 77°F). Reconstituted suspension: refrigerate 2°C to 8°C (36°F to 46°F); use within 8 hours.
BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Nab-Paclitaxel is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Nab-Paclitaxel. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.
🏥 Medicare Coverage
Medicare Part B covers this IV medication when administered in a clinical setting. Medicaid coverage varies by state.
🆓 Patient Assistance
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.
Prior Authorization Patient Assistance Insurance & Savings Medication Costs
Frequently Asked Questions — Nab-Paclitaxel
Nab-paclitaxel (brand name Abraxane) is an albumin-bound formulation of paclitaxel that avoids the solvent Cremophor EL used in conventional paclitaxel. It is approved for metastatic breast cancer, non-small cell lung cancer (with carboplatin), and pancreatic cancer (with gemcitabine).
No. While both contain paclitaxel as the active ingredient, nab-paclitaxel (Abraxane) and conventional paclitaxel are NOT interchangeable. They have different dosing, administration times, premedication requirements, and toxicity profiles. Substituting them on a mg-per-mg basis can cause serious harm.
The most common serious side effects are peripheral neuropathy (numbness/tingling, which can be cumulative) and neutropenia (low white blood cell count). Both may require dose reduction.
Nab-paclitaxel (Abraxane) is covered by Medicare Part B and most commercial insurance for approved indications with prior authorization. Generic versions may have different formulary status.
Related Medications & Conditions
Related Medications
Paclitaxel (conventional) · Gemcitabine · Carboplatin · Docetaxel
Related Conditions
Metastatic breast cancer · Non-small cell lung cancer · Pancreatic cancer